Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots

Croom, Hayley A; Richards, Kim M.; Best, Susan J.; Francis, Barbara; Johnson, Elizabeth L.; Dax, Elizabeth M.; Wilson, Kim

doi:10.1016/j.jcv.2005.12.002

Cited by 36 publications

(34 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Villar et al 36 , e.g., recorded almost equivalent elution capacities for all buffers used, but PBS/BSA 0.5% resulted in the lowest level of non-specific reactivity. A very similar observation was made by Croom and co-workers 44 when applying the specimen diluent of the Genetics Systems rLAV EIA for the elution of anti-HCV antibodies from DBS. Since the risk of sample degradation is exceedingly low in the first hours after preparation of DBS (see above), it was decided to incubate the spots O/N at ambient temperature and to support the elution process by gentle end-over-end mixing.…”

Section: Parameterssupporting

confidence: 77%

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Grüner

Stambouli

Roß

2015

JoVE

125

110

View full text Add to dashboard Cite

The idea of collecting blood on a paper card and subsequently using the dried blood spots (DBS) for diagnostic purposes originated a century ago. Since then, DBS testing for decades has remained predominantly focused on the diagnosis of infectious diseases especially in resourcelimited settings or the systematic screening of newborns for inherited metabolic disorders and only recently have a variety of new and innovative DBS applications begun to emerge. For many years, pre-analytical variables were only inappropriately considered in the field of DBS testing and even today, with the exception of newborn screening, the entire pre-analytical phase, which comprises the preparation and processing of DBS for their final analysis has not been standardized. Given this background, a comprehensive step-by-step protocol, which covers al the essential phases, is proposed, i.e., collection of blood; preparation of blood spots; drying of blood spots; storage and transportation of DBS; elution of DBS, and finally analyses of DBS eluates. The effectiveness of this protocol was first evaluated with 1,762 coupled serum/DBS pairs for detecting markers of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections on an automated analytical platform. In a second step, the protocol was utilized during a pilot study, which was conducted on active drug users in the German cities of Berlin and Essen.

show abstract

Section: Parameterssupporting

confidence: 77%

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Grüner

Stambouli

Roß

2015

JoVE

125

110

View full text Add to dashboard Cite

show abstract

“…The samples came from clinics run by community addition services. Group 4 consisted of 65 DBS taken from known chronic patients (tested anti-HCV and HCV PCR positive for >1 year) and group 5 consisted of 68 DBS from resolved patients (tested anti-HCV and HCV PCR negative for an average of 6 years, range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. The patients chosen for each group had had previous HCV results from plasma samples on record at WoSSVC.…”

Section: Patient Dbs Samplesmentioning

confidence: 99%

“…1 It can be difficult to obtain a conventional blood sample from people who inject drugs (PWID) and dried blood spot (DBS) testing is a noninvasive method that can be used for antibody and PCR testing. [2][3][4] In specialist drug service settings in Scotland, it has contributed greatly to the rise in the number of HCV diagnoses. 1 DBS testing has also been used successfully for surveillance purposes.…”

Section: Introductionmentioning

confidence: 99%

A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots

Shepherd

Kean

Hutchinson

et al. 2013

Journal of Clinical Virology

View full text Add to dashboard Cite

This version is available at https://strathprints.strath.ac.uk/42887/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.ukThe Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. a b s t r a c tBackground: DBS testing has been used successfully to detect HCV antibody positive individuals. Determining how long someone has been infected is important for surveillance initiatives. Antibody avidity is a method that can be used to calculate recency of infection. Objectives: A HCV avidity assay was evaluated for both plasma and DBS. Study design: To measure antibody avidity a commercial HCV ELISA was modified using 7 M urea. The plasma samples were split into: group 1 (recently infected N = 19), group 2 (chronic carrier N = 300) and group 3 (resolved infection N = 82). Mock DBS made from group 1 (N = 12), group 2 (N = 50), group 3 (N = 25) and two seroconverter panels were evaluated. 133 DBS taken from patients known to have a resolved infection or be a chronic carrier were also tested.Results: The avidity assay cut-off was set at AI ≤ 30 for a recent infection. Using sequential samples the assay could detect a recent infection in the first 4-5 months from the point of infection. Most of the false positive results (AI < 30 among cases known not to have had recent infection) were detected among known resolved infections, in both the plasma and DBS; as a result, a testing algorithm has been designed incorporating both PCR and two dilution factors. The sensitivity and specificity of the assay on plasma was 100% and 99.3%, respectively, while DBS had 100% sensitivity and 98.3% specificity. Conclusion:The HCV avidity assay can be used to distinguish between chronic and recent infection using either plasma or DBS as the sample type.

show abstract

“…This method is a good alternative to the classical ones due to relative noninvasiveness, easy realization, simple sample treatment and storage, very low volumes of biomaterials applications [2]. In medical practice this approach was lately effectively adapted for infectious disease diagnostics [3,4], including human immunodeficiency virus [5][6][7][8], hepatitis [9][10][11][12], and flaviviridae [13]. Moreover, this technique is suggested as the major one for creating biobanks of humans [14].…”

Section: Introductionmentioning

confidence: 99%

Comparative research of effectiveness of cellulose and fiberglass porous membrane carriers for bio sampling in veterinary and food industry monitoring

Gusev

Vasyukova

Zakharova

et al. 2017

AIP Conference Proceedings

View full text Add to dashboard Cite

Abstract. The aim of proposed research is to study the applicability of fiberglass porous membrane materials in a new strip format for dried blood storage in food industry monitoring. A comparative analysis of cellulosic and fiberglass porous membrane materials was carried out to obtain dried samples of serum or blood and the possibility of further species-specific analysis. Blood samples of Sus scrofa were used to study the comparative effectiveness of cellulose and fiberglass porous membrane carriers for long-term biomaterial storage allowing for further DNA detection by real-time polymerase chain reaction (PCR) method. Scanning electron microscopy of various membranes -native and with blood samples -indicate a fundamental difference in the form of dried samples. Membranes based on cellulosic materials sorb the components of the biological fluid on the surface of the fibers of their structure, partially penetrating the cellulose fibers, while in the case of glass fiber membranes the components of the biological fluid dry out as films in the pores of the membrane between the structural filaments. This fundamental difference in the retention mechanisms affects the rate of dissolution of the components of dry samples and contributes to an increase in the efficiency of the desorption process of the sample before subsequent analysis. Detecting of pig DNA in every analyzed sample under the performed Real-time PCR as well as good state of the biomaterial preservation on the glass fiber membranes was clearly demonstrated. Good biomaterials preservation has been revealed on the test cards for 4 days as well as for 1 hour.

show abstract

Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots

Cited by 36 publications

References 13 publications

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots

Comparative research of effectiveness of cellulose and fiberglass porous membrane carriers for bio sampling in veterinary and food industry monitoring

Contact Info

Product

Resources

About